Search

Cytoreductive surgery for advanced ovarian cancer is safe in older women, even those who present with frailty.

… Thursday, September 19, 2019 Cytoreductive surgery for advanced ovarian cancer is safe in older women, even those who present with frailty, according to our recent prospective study of 42 patients treated at Memorial Sloan Kettering Cancer Center. Despite a high rate of preoperative impairments, there

The first-ever clinical trial of a new kind of drug, called pirtobrutinib or LOXO-305, has shown promising results in a phase I/II study.

… Friday, March 5, 2021 Summary Pirtobrutinib (also known as LOXO-305), a type of drug called a BTK inhibitor, appears to be effective in many people with blood cancers called B cell malignancies. The incidence of severe side effects for the drug is also very low. The first-ever clinical trial of a new

The $50 million donation from Mike and Maria Repole and the Nonna’s Garden Foundation will support cancer care on Long Island and significantly advance research efforts.

… Monday, November 8, 2021 Memorial Sloan Kettering Cancer Center (MSK) today announced a generous $50 million gift from Mike and Maria Repole and the Nonna’s Garden Foundation to establish The Nonna’s Garden Foundation Initiative for Cancer Care and Research at MSK. The initiative will support several

The Thrivers event at Memorial Sloan Kettering celebrates Bone Marrow Transplant recipients on their return to health.

… Thursday, October 4, 2018 Family at BMT Thriver event Around 700 people joined the 23rd annual celebration for blood and marrow transplant thrivers at 583 Park Avenue, an event space in New York City. Bridget Anderson When Bridget Anderson learned there were no donor matches for a transplant to treat

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.

… Monday, September 9, 2019 Bottom Line: Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer

The Gene: An Intimate History is a new four-hour documentary from the award-winning Ken Burns team and PBS, adapted from the award-winning book of the same name by Siddhartha Mukherjee, MD, DPhil. Memorial Sloan Kettering’s Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology, is a featured expert.

… Monday, April 13, 2020 The Gene: An Intimate History is a new four-hour documentary from the award-winning Ken Burns team and PBS, adapted from the award-winning book of the same name by Siddhartha Mukherjee, MD, DPhil. The two-part series brings to life a historical biography of the human genome while

Memorial Sloan Kettering Cancer Center recently published two retrospective studies with practice-changing insights for improving the treatment and surveillance of patients with oropharyngeal cancer.

… Friday, December 19, 2025 Teams of head and neck radiation oncologists, surgical oncologists and medical oncologists at Memorial Sloan Kettering Cancer Center (MSK) recently published two retrospective studies with practice-changing insights for improving the treatment and surveillance of patients with

Signet ring cell cancer (SRCC) was detected in the vast majority of patients with CDH1 mutations following total gastrectomy.

… Monday, July 11, 2022 Signet ring cell cancer (SRCC) was detected in the vast majority of patients with CDH1 mutations following total gastrectomy, according to a study Memorial Sloan Kettering Cancer Center (MSK) physicians published in JAMA Surgery .  (1) With the increasing availability of genomic

Learn about how MSK staff members recently participated in the 2021 Forbes China Healthcare Summit and spoke about how the war on cancer must be fought internationally with teams collaborating across political boundaries.

… Thursday, September 23, 2021 No one doctor, institution, or country can cure cancer on their own. The war on cancer must be fought internationally with teams collaborating across political boundaries. That was the key message of the 2021 Forbes China Healthcare Summit, which brought together leaders

Intensity-modulated radiation therapy (IMRT) confers a lower risk of femoral fracture in patients with primary soft tissue sarcoma of the thigh or groin, despite a higher dose of radiation to the target volume compared to conventional radiation.

… Monday, May 13, 2019 Intensity-modulated radiation therapy (IMRT) confers a lower risk of femoral fracture in patients with primary soft tissue sarcoma of the thigh or groin, despite a higher dose of radiation to the target volume compared to conventional radiation, according to the results of our study